GlobeNewsWire
16 Jun 2026, 21:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADC Therapeutics' Phase 3 LOTIS-5 trial for ZYNLONTA recorded 27 deaths in the treatment arm compared to nine in the immunotherapy arm. — High mortality rates in a pivotal Phase 3 trial suggest severe safety concerns, likely compromising regulatory approval and commercial viability.
-0.90ADC Therapeutics' stock price fell approximately 66.56% over two trading sessions following the release of the LOTIS-5 data. — The drastic price collapse confirms a massive loss in market capitalization and investor confidence.
-0.60Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud or unlawful business practices related to these developments. — The prospect of class-action litigation introduces additional legal liability and financial risk beyond the clinical failure.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a potential class action investigation for securities fraud following a 66% stock price crash due to poor trial data.
The company is the subject of an investigation by a law firm on behalf of investors.
The company is the subject of an investigation by a law firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
